FCCC LOGO Faculty Publications
Hess LM , Barakat R , Tian C , Ozols RF , Alberts DS
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Gynecologic Oncology. 2007 Nov;107(2) :260-265
PMID: ISI:000250654900020   
Back to previous list
Abstract
Objective. Platinum/Paclitaxel-based chemotherapy is a current treatment for advanced epithelial ovarian cancer. We sought to explore the association between weight change during treatment and survival, as well as the association between pre-chemotherapy body mass index (BMI) and survival. Methods. A retrospective data review was conducted of 792 advanced ovarian cancer patients who participated in a phase III randomized trial of cisplatin/paclitaxel versus carboplatin/paclitaxel. Pre-chemotherapy BMI was calculated following surgery. Weight change was defined as the ratio of body weight at completion of protocol therapy to pre-chemotherapy body weight. Progression-free survival (PFS) and overall survival (OS), classified by BMI or relative weight change, were estimated by Kaplan-Meier, and associations were assessed using a Cox model controlled for known prognostic variables (age, race, performance status, histology, tumor grade, tumor residual and treatment group). Results. There was no association between pre-chemotherapy BMI and survival. There was a significant relationship between median OS and weight change as follows: > 5% decrease=48.0 months; 0-5% decrease=49.3 months; 0-5% increase=61.1 months; and > 5% inerease=68.2 months. Adjusted for covariates, the relative risk of death increased by 7% for each 5% decrease in body weight (HR=0.93, 95% CI=0.88-0.99; p=0.013). Conclusions. Change of body weight during primary chemotherapy was a strong prognostic factor for overall survival. Loss of body weight during primary therapy is an indicator for poor OS; weight gain is an indicator for improved survival. This study supports the development of strategies to minimize weight loss that can be assessed in a prospective, randomized study to improve patient outcomes. (c) 2007 Elsevier Inc. All rights reserved.
Notes
ISI Document Delivery No.: 227KF Times Cited: 0 Cited Reference Count: 24 Cited References: ANDRYKOWSKI MA, 2007, CANCER EPIDEM BIOMAR, V16, P430 CALLE EE, 2003, NEW ENGL J MED, V348, P1625 COLEMAN RL, 1997, CANCER J SCI AM, V3, P246 DELL DD, 2002, CLIN J ONCOL NURS, V6, P235 DOYLE C, 2006, CA-CANCER J CLIN, V56, P323 ESTES JM, 2006, J AM COLL SURGEONS, V203, P527 FITCH M, 2002, CAN ONCOL NURS J, V12, P152 GADDUCCI A, 2001, ANTICANCER RES, V21, P2941 GIL KM, 2006, GYNECOL ONCOL, V103, P247 HAINSWORTH JD, 1998, EUR J CANCER, V34, P654 HATCH KD, 1991, CANCER, V68, P269 HOMER D, 1999, APPL SURVIVAL ANAL R HOYO C, 2005, CANCER CAUSE CONTROL, V16, P955 IRWIN ML, 2003, CANCER, V97, P1746 KEY TJ, 2003, J NATL CANCER I, V95, P1218 KJAERBYETHYGESEN A, 2006, CANCER EPIDEM BIOMAR, V15, P798 MODESITT SC, 2005, OBSTET GYNECOL SURV, V60, P683 OZOLS RF, 2003, J CLIN ONCOL, V21, P3194 PAVELKA JC, 2006, CANCER, V107, P1520 RIEDINGER JM, 2006, ANN ONCOL, V17, P1234 RODRIGUEZ C, 2002, CANCER EPIDEM BIOMAR, V11, P822 STIERER M, 1993, ANN SURG, V218, P13 TAKAI K, 2003, ORG LETT, V5, P653 ZHANG M, 2005, CANCER EPIDEM BIOMAR, V14, P1307 Hess, L. M. Barakat, R. Tian, C. Ozols, R. F. Alberts, D. S. ACADEMIC PRESS INC ELSEVIER SCIENCE; 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA